Retinal Protection Sciences
Retinal Protection Sciences (RPS) is developing the first preventative and therapeutic treatment for the most important and widespread causes of irreversible blindness. These include age-related macular degeneration (AMD), diabetic retinopathy (DR), open angle glaucoma (OAG) and inherited retinal degenerations (IRD ) such as retinitis pigmentosa (RP). RPS was founded by Jeffrey K Luttrull, MD in 2016 to commercialize the intellectual property developed by Dr. Luttrull, based on his nearly 20 years of groundbreaking advancements in the field of retinal laser treatment. Dr. Luttrull’s innovative work in restorative retinal therapy has led to recognition of Dr. Luttrull as one of the world’s leading authorities on laser treatment and restorative treatment of the retina.
RPS believes that the future of medical care is in disease prevention and functional regeneration. RPS believes this is done best when the body can be encouraged to heal itself by activating powerful natural reparative processes. When this is successful, the natural physiologic response to disease is perfectly tailored to the problem, maximally safe and effective, avoiding the risks and side effects of drugs and surgery.
While our bodies have powerful and highly effective mechanisms for repair, healing and regeneration, many key drivers of the chronic progressive diseases that plague the modern world escape the attention of these potentially healing processes. Sometimes this occurs to the extent that the reparative processes themselves become dysfunctional to the point of failure.
RPS is developing a class 2b medical device and system (“SAPRA™”) for the treatment of chronic progressive retinopathies (CPRs). SAPRA™ stands for “Safe-Pulse™ Retinal Activation™”. The principal components of the SAPRA™ include a fundus camera, laser, software, automated safety technology and other proprietary elements.
SAPRA™ is designed to activate reparative processes in the cells and tissues of the eye effectively, and without the potential for harm. SAPRA™ will provide the next generation of Retinal Protective Therapy using patented processes in a highly automated format requiring only a few seconds for treatment in maximal patient safety and comfort.
While the causes of AMD, DR, OAG and RP are different, all CPRs are neurodegenerative diseases, and thus have much in common. SAPRA™ is designed to address these fundamental commonalities to reverse the disease process, improve visual function, and prevent visual loss.
Spark Notes summary: Think of SAPRA™ as the therapeutic analogue of the OCT. SAPRA™ can be be used for everything the OCT can be used for, and more. However, SAPRA™ generates a continuous revenue stream to the Company.
RPS anticipates completion of SAPRA™ regulatory approval in 2019 and looks forward to providing those at risk for vision loss with this new, innovative and powerful tool.
SAPRATM’s innovative design, use and technologies are patent protected. Issued patents include:
- US 9,381,115 SYSTEM AND PROCESS FOR RETINA PHOTOTHERAPY
- US 9,168,174 PROCESS FOR RESTORING RESPONSIVENESS TO MEDICATION IN TISSUES OF LIVING ORGANISMS
- US 9,381,116 SUBTHRESHOLD MICROPULSE PROPHYLACTIC TREATMENT FOR CHRONIC PROGRESSIVE RETINAL DISEASES
- US Patent No. 9,427,602. Pulsating electromagnetic and ultrasound for stimulating targeted heat shock proteins for achieving retinal repair. Filed Oct 26, 2015; issued August 30, 2016.
- US Patent No. 9,962,291 SYSTEM AND PROCESS FOR NEUROPROTECTIVE THERAPY FOR GLAUCOMA Filed: August 9, 2016, awarded May 1, 2018.
- U.S. Patent No. 10,076,671 Apparatus for retinal phototherapy, filed July 1, 2016; awarded Sept 2018.
Appropriate protection has been sought for each of these US patents in other key jurisdictions throughout the world. Additionally, there are numerous applications pending that continue, expand and extend the core intellectual property of these patents.
Jeffrey K Luttrull, MD Founder, Chief Executive and Medical Officer
Benjamin WL Margolis, MA Chief Engineering Officer
David B Chang, PhD Chief Scientific Officer
Harry Carneal Chief of Business Development